JP7046940B2 - 神経栄養因子チロシンキナーゼ受容体阻害剤として用いられるアミノピラゾロピリミジン化合物 - Google Patents

神経栄養因子チロシンキナーゼ受容体阻害剤として用いられるアミノピラゾロピリミジン化合物 Download PDF

Info

Publication number
JP7046940B2
JP7046940B2 JP2019522962A JP2019522962A JP7046940B2 JP 7046940 B2 JP7046940 B2 JP 7046940B2 JP 2019522962 A JP2019522962 A JP 2019522962A JP 2019522962 A JP2019522962 A JP 2019522962A JP 7046940 B2 JP7046940 B2 JP 7046940B2
Authority
JP
Japan
Prior art keywords
group
hydroxy
alkyl
phenyl
independently selected
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019522962A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019537588A (ja
JP2019537588A5 (enExample
Inventor
祝力
胡遠東
呉偉
戴麗光
段小偉
楊艷青
孫穎慧
韓永信
彭勇
孔凡勝
羅鴻
楊玲
徐宏江
郭猛
仲兆柏
王善春
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Original Assignee
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chia Tai Tianqing Pharmaceutical Group Co Ltd filed Critical Chia Tai Tianqing Pharmaceutical Group Co Ltd
Publication of JP2019537588A publication Critical patent/JP2019537588A/ja
Publication of JP2019537588A5 publication Critical patent/JP2019537588A5/ja
Application granted granted Critical
Publication of JP7046940B2 publication Critical patent/JP7046940B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2019522962A 2016-10-28 2017-10-27 神経栄養因子チロシンキナーゼ受容体阻害剤として用いられるアミノピラゾロピリミジン化合物 Active JP7046940B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN201610970314.3 2016-10-28
CN201610970314 2016-10-28
CN201710044000 2017-01-21
CN201710044000.5 2017-01-21
PCT/CN2017/108100 WO2018077246A1 (zh) 2016-10-28 2017-10-27 用作神经营养因子酪氨酸激酶受体抑制剂的氨基吡唑并嘧啶化合物

Publications (3)

Publication Number Publication Date
JP2019537588A JP2019537588A (ja) 2019-12-26
JP2019537588A5 JP2019537588A5 (enExample) 2022-01-21
JP7046940B2 true JP7046940B2 (ja) 2022-04-04

Family

ID=62024344

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019522962A Active JP7046940B2 (ja) 2016-10-28 2017-10-27 神経栄養因子チロシンキナーゼ受容体阻害剤として用いられるアミノピラゾロピリミジン化合物

Country Status (15)

Country Link
US (1) US10829492B2 (enExample)
EP (1) EP3533796B1 (enExample)
JP (1) JP7046940B2 (enExample)
KR (1) KR102616249B1 (enExample)
CN (1) CN109890820B (enExample)
AU (1) AU2017348826B2 (enExample)
CA (1) CA3041942C (enExample)
DK (1) DK3533796T3 (enExample)
ES (1) ES2896943T3 (enExample)
HU (1) HUE057733T2 (enExample)
MX (1) MX380283B (enExample)
PL (1) PL3533796T3 (enExample)
PT (1) PT3533796T (enExample)
RU (1) RU2764523C2 (enExample)
WO (1) WO2018077246A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3658148T (pt) * 2017-07-28 2024-08-26 Turning Point Therapeutics Inc Compostos macrocíclicos e utilizações dos mesmos
KR102619444B1 (ko) 2017-08-23 2023-12-29 치아타이 티안큉 파마수티컬 그룹 주식회사 아미노피라졸 및 피리미딘을 함유하는 마크로사이클 및 그의 약학적 조성물 및 용도
CN108794370A (zh) * 2018-07-31 2018-11-13 上海弈柯莱生物医药科技有限公司 一种拉罗替尼中间体的制备方法
TW202033526A (zh) * 2018-12-07 2020-09-16 大陸商貝達藥業股份有限公司 用作酪胺酸激酶抑制劑的化合物、包含其的藥物組合物及其用途
WO2020187291A1 (zh) 2019-03-19 2020-09-24 华中师范大学 吡唑并嘧啶化合物和药物组合物及其应用
CN112979654B (zh) * 2019-12-16 2024-03-19 赛诺哈勃药业（成都）有限公司 杂芳基稠环化合物、其制备方法及应用
WO2021249450A1 (zh) * 2020-06-11 2021-12-16 贝达药业股份有限公司 酪氨酸激酶抑制剂的盐型、晶型、药物组合物及其用途
CN111620881B (zh) * 2020-07-08 2023-03-31 浙江合聚生物医药有限公司 拉罗替尼衍生物及其制备方法和应用
CN113563343B (zh) * 2020-07-27 2022-05-24 杭州邦顺制药有限公司 取代的吡唑并[1,5-a]嘧啶化合物及其用途
CN112010860B (zh) * 2020-08-05 2023-03-10 南京纳丁菲医药科技有限公司 苄氧基吡唑并嘧啶化合物和药物组合物及其应用
CN114437075B (zh) * 2020-11-03 2026-01-30 上海瑶琪生物科技有限公司 用作ntrk激酶抑制剂的化合物及其应用
CN113200963A (zh) * 2021-03-31 2021-08-03 广东石油化工学院 N-(吡咯基)-3-吡唑基胺及其制备方法
EP4335441B1 (en) * 2021-05-03 2025-05-28 JBKLAB Co., Ltd. Pharmaceutical composition for preventing, alleviating, or treating cancer, containing 2,6-dichloro-4-(4-(4-hydroxycyclohexylamino)-7h-pyrrolo[2,3-d]pyrimidin-5-yl)phenol as active ingredient
CN117751121A (zh) * 2021-07-30 2024-03-22 正大天晴药业集团股份有限公司 氨基吡唑并嘧啶化合物的晶体
WO2023011616A1 (zh) * 2021-08-06 2023-02-09 正大天晴药业集团股份有限公司 氨基吡唑并嘧啶化合物在治疗trk激酶介导的肿瘤中的用途
CN117088800B (zh) * 2023-08-18 2024-05-28 龙曦宁（上海）医药科技有限公司 一种5-甲基吡咯烷-3-醇盐酸盐的制备方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007513099A (ja) 2003-12-04 2007-05-24 メルク　パテント　ゲゼルシャフト　ミット　ベシュレンクテル　ハフトング アミン誘導体
JP2012532888A (ja) 2009-07-09 2012-12-20 アレイ バイオファーマ、インコーポレイテッド ＴＲＫキナーゼ阻害剤としての置換ピラゾロ［１，５−ａ］ピリミジン化合物
WO2013028263A1 (en) 2011-08-24 2013-02-28 Glaxosmithkline Llc Pyrazolopyrimidine derivatives as pi3 kinase inhibitors

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2722418C (en) 2008-05-13 2013-09-17 Irm Llc Fused nitrogen containing heterocycles and compositions thereof as kinase inhibitors
CA2727250A1 (en) 2008-07-01 2010-01-07 Genentech, Inc. Bicyclic heterocycles as mek kinase inhibitors
SI2350075T1 (sl) 2008-09-22 2014-06-30 Array Biopharma, Inc. Substituirane imidazo (1,2b)piridazinske spojine kot Trk kinazni inhibitorji
CN102264736B (zh) * 2008-10-22 2013-08-14 阵列生物制药公司 作为TRK激酶抑制剂的取代的吡唑并[1,5-a]嘧啶化合物
WO2012034095A1 (en) * 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
BR112013021638A2 (pt) 2011-02-25 2016-08-02 Irm Llc "compostos inibidores de trk, seu uso e composições que os compreendem"
KR20140105508A (ko) 2011-12-12 2014-09-01 닥터 레디스 레보러터리즈 리미티드 트로포미오신 수용체 키나제(Trk) 억제제인 치환된 피라졸로[1,5-a]피리딘
MX362181B (es) 2013-02-19 2019-01-08 Ono Pharmaceutical Co Compuesto inhibidor de cinasa del receptor de tropomiosina (trk).
EP2970288A1 (en) * 2013-03-15 2016-01-20 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
CN104650092B (zh) 2013-11-16 2017-11-10 广东东阳光药业有限公司 取代的杂芳基化合物及其组合物和用途
HUE046727T2 (hu) * 2013-12-06 2020-03-30 Vertex Pharma Az ATR-kináz inhibitoraként használható vegyület, 2-amino-6-fluoro-N-[5-fluoro-piridin-3-IL]-pirazolo-[1,5-A]-pirimidin-3-karboxamid, ennek elõállítása, különbözõ szilárd formái és ezek radioaktív nyomjelzett származékai
HUE067779T2 (hu) * 2014-12-15 2024-11-28 Cmg Pharmaceutical Co Ltd Kondenzált gyûrûs heteroaril vegyületek és azok felhasználása TRK inhibitorokként

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007513099A (ja) 2003-12-04 2007-05-24 メルク　パテント　ゲゼルシャフト　ミット　ベシュレンクテル　ハフトング アミン誘導体
JP2012532888A (ja) 2009-07-09 2012-12-20 アレイ バイオファーマ、インコーポレイテッド ＴＲＫキナーゼ阻害剤としての置換ピラゾロ［１，５−ａ］ピリミジン化合物
WO2013028263A1 (en) 2011-08-24 2013-02-28 Glaxosmithkline Llc Pyrazolopyrimidine derivatives as pi3 kinase inhibitors

Also Published As

Publication number Publication date
PL3533796T3 (pl) 2022-01-17
ES2896943T3 (es) 2022-02-28
DK3533796T3 (da) 2021-11-08
MX2019004847A (es) 2019-08-29
AU2017348826A1 (en) 2019-05-23
MX380283B (es) 2025-03-12
RU2019114600A3 (enExample) 2021-02-20
CN109890820A (zh) 2019-06-14
CA3041942C (en) 2023-03-14
RU2764523C2 (ru) 2022-01-18
US20190352306A1 (en) 2019-11-21
KR102616249B1 (ko) 2023-12-21
BR112019008656A8 (pt) 2022-06-07
JP2019537588A (ja) 2019-12-26
HUE057733T2 (hu) 2022-06-28
CN109890820B (zh) 2020-11-03
PT3533796T (pt) 2021-11-18
RU2019114600A (ru) 2020-11-30
CA3041942A1 (en) 2018-05-03
EP3533796A4 (en) 2020-06-03
EP3533796B1 (en) 2021-09-29
US10829492B2 (en) 2020-11-10
BR112019008656A2 (pt) 2019-07-09
WO2018077246A1 (zh) 2018-05-03
KR20190067913A (ko) 2019-06-17
AU2017348826B2 (en) 2021-12-02
EP3533796A1 (en) 2019-09-04

Similar Documents

Publication Publication Date Title
EP3533796B1 (en) Amino pyrazolopyrimidine compound used as neurotrophic factor tyrosine kinase receptor inhibitor
JP7644517B2 (ja) Ｋｒａｓ突然変異型タンパク質阻害剤
RU2743074C2 (ru) Соединения, активные по отношению к бромодоменам
JP6165977B2 (ja) ヘテロアリールピリドン及びアザ−ピリドンアミド化合物
KR101813830B1 (ko) 친전자성 작용기를 갖는 헤테로아릴 피리돈 및 아자-피리돈 화합물
CN117917410A (zh) pan-KRAS降解剂及其制备方法和应用
JP5511668B2 (ja) ピラジン−２−イル−ピリジン−２−イル−アミンとピラジン−２−イル−ピリミジン−４−イル−アミン化合物およびそれらの使用
CN103582638B (zh) 杂芳基并嘧啶类衍生物、其制备方法和用途
KR20200101389A (ko) 메닌-mll 상호작용의 엑소-아자 스피로 억제제
CN116783183B (zh) 用于治疗贫血和癌症的vhl抑制剂
US20240150343A1 (en) Compound having brd4 inhibitory activity, preparation method therefor and use thereof
IL293107A (en) Adenosine receptor antagonist compounds
WO2024149389A1 (zh) 取代桥环类抑制剂及其制备方法和应用
TWI344468B (en) Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors
CN113045569B (zh) 用作ret激酶抑制剂的化合物及其应用
AU2024289347A1 (en) Nmt inhibitor, and preparation method therefor and use thereof
IL291396B2 (en) MLL1 inhibitors and anticancer drugs
TW202322812A (zh) 吡唑［３，４－ｄ］嘧啶－３－酮類化合物、包含其的藥物組合物及其醫藥用途
CN117597346A (zh) Nek7抑制剂
CN116813646A (zh) 取代桥环类抑制剂及其制备方法和应用
CN116135851B (zh) 一种芳香胺化合物及其应用
US20250276966A1 (en) Nitrogen-Linked Benzisoxazole Sulfonamide Derivatives
HK40002935A (en) Amino pyrazolopyrimidine compound used as neurotrophic factor tyrosine kinase receptor inhibitor
HK40002935B (en) Amino pyrazolopyrimidine compound used as neurotrophic factor tyrosine kinase receptor inhibitor
BR112019008656B1 (pt) Composto de aminopirazolopirimidina, composição farmacêutica que compreende o mesmo e uso do dito composto para a profilaxia ou o tratamento de uma doença mediada por receptor de tirosina quinase de fator neurotrófico

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20201023

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210916

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211012

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20220112

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220315

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220323

R150 Certificate of patent or registration of utility model

Ref document number: 7046940

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250